Sareum Holdings PLC (LSE: SAR) is a drug development company advancing small-molecule kinase inhibitors for cancer and autoimmune diseases. Its pipeline includes SDC-1801 and SDC-1802, targeting JAK and TYK2 pathways. Sareum partners with larger pharma to advance clinical-stage assets in high-value therapeutic areas.